Sample conc. (µg/mL) Compound No.	Growth inhibition %						IC₅₀ (µM/L)
Sample conc. (µg/mL) Compound No.	50	25	12.5	6.25	3.13	1.6	IC₅₀ (µM/L)
2	69.06	52.75	30.68	16.86	7.14	1.53	78.52
3	58.28	47.59	30.12	21.88	10.66	4.22	>100
4	62.47	46.84	37.45	25.22	14.08	8.56	>100
5	53.68	40.22	28.46	13.64	5.78	1.87	>100
6	72.05	45.17	21.46	8.28	2.62	100.00	>100
7	71.61	50.54	36.18	27.03	20.66	9.49	81.66
8	71.41	50.76	36.27	14.04	5.18	1.85	86.48
9	74.68	48.14	29.06	10.44	3.82	0.00	90.54
10	76.22	45.61	30.19	12.66	4.78	1.83	68.75
11	70.92	47.86	31.05	21.84	10.47	5.62	59.87
12	75.42	50.25	27.47	18.64	9.43	3.76	48.26
13	65.02	37.83	20.46	8.22	2.68	0.00	79.96
14	68.66	33.21	9.35	2.86	0.00	0.00	84.59
15	79.02	65.77	41.36	20.85	10.28	3.54	44.37
16	84.06	63.33	37.77	20.52	12.47	5.81	57.63
17	62.71	53.62	37.46	18.81	6.17	2.35	47.03
18	86.18	71.67	58.64	37.86	28.08	12.14	29.46
19	84.06	73.17	60.24	52.42	36.83	11.66	13.46
20	89.46	74.83	61.25	41.18	30.19	11.27	20.98
21	72.82	60.69	63.29	24.16	17.25	10.88	46.41
22	82.66	70.58	51.37	21.07	9.14	1.87	24.80
23	89.14	72.82	61.28	52.69	30.26	10.50	11.94
24	93.03	81.77	72.32	59.05	43.28	28.46	10.82
25	68.46	42.54	28.79	14.28	5.32	1.87	99.08
26	59.46	47.67	38.31	25.22	13.96	7.64	96.76
27	61.06	36.97	15.82	3.15	0.00	0.00	>100
28	65.06	51.89	32.54	18.76	9.47	2.62	62.14
29	78.22	61.86	45.08	19.22	10.47	3.84	40.40
Doxorubicin	90.76	88.45	84.26	77.78	70.82	55.16	8.90